Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on April 13, 2021, at 8:45 a.m. ET. CEO Ted White will lead the presentation, which highlights Verrica's focus on dermatology therapeutics. The company is advancing VP-102 for treating molluscum and warts, and VP-103 for plantar warts. Additionally, Verrica has partnered with Lytix Biopharma to develop LTX-315 for dermatologic oncology. A live webcast and replay will be available for those unable to attend the event.

Positive

• Verrica is advancing its late-stage product candidate VP-102 for multiple skin conditions, addressing significant unmet needs.
• The company is also developing VP-103 for plantar warts, expanding its product offerings.
• Verrica has secured a worldwide license agreement with Lytix Biopharma for LTX-315, indicating growth potential in dermatologic oncology.

Negative

• None.

WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will present a business overview at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021, at 8:45 a.m. ET.

Participants may access a live webcast of the event through the following link:
https://wsw.com/webcast/needham107/vrca/2245496.

The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com. The webcast replay will be available shortly after conclusion of the event for 30 days.

About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s late-stage product candidate, VP-102, is in development to treat molluscum, common warts and external genital warts, three of the largest unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. The Company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology conditions. For more information, Visit www.verrica.com.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

A. Brian Davis
Chief Financial Officer
484.453.3300 ext. 103
info@verrica.com

William Windham
Solebury Trout
646.378.2946
wwindham@soleburytrout.com

Media:

Zara Lockshin
Solebury Trout
646.378.2960
zlockshin@soleburytrout.com

FAQ

When is Verrica Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

Verrica Pharmaceuticals is presenting on April 13, 2021, at 8:45 a.m. ET.

What product candidates is Verrica Pharmaceuticals developing?

Verrica is developing VP-102 for molluscum and warts, and VP-103 for plantar warts.

What partnership has Verrica Pharmaceuticals recently entered?

Verrica has entered a worldwide license agreement with Lytix Biopharma to develop LTX-315 for dermatologic oncology.

How can I access the webcast for Verrica's presentation?

The live webcast can be accessed through Verrica's website and the provided conference link.

What is the main focus of Verrica Pharmaceuticals?

Verrica focuses on developing medications for skin diseases requiring medical interventions.